Laura Lk Keller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3251049/publications.pdf

Version: 2024-02-01

430874 677142 1,557 23 18 22 citations h-index g-index papers 25 25 25 2631 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 2019, 19, 553-567.	28.4	393
2	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. British Journal of Cancer, 2021, 124, 345-358.	6.4	238
3	NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. ELife, 2016, 5, .	6.0	231
4	Biology and clinical relevance of EpCAM. Cell Stress, 2019, 3, 165-180.	3.2	127
5	Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2019, 137, 1-6.	2.0	79
6	Monitoring of <i>KRAS</i> -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget, 2017, 8, 38056-38060.	1.8	71
7	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Research, 2022, 82, 349-358.	0.9	57
8	Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS -mutated lung adenocarcinoma. Lung Cancer, 2016, 100, 1-4.	2.0	53
9	Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Molecular Aspects of Medicine, 2020, 72, 100817.	6.4	49
10	RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Research, 2013, 15, R6.	5.0	32
11	A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation. Cell Chemical Biology, 2019, 26, 1544-1558.e6.	5. 2	32
12	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clinical and Experimental Metastasis, 2022, 39, 159-179.	3.3	30
13	Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF -Mutated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, e109-e112.	1.1	27
14	Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities. Antibodies, 2019, 8, 8.	2.5	26
15	Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers, 2019, 11, 1685.	3.7	23
16	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Acta Dermato-Venereologica, 2019, 99, 206-210.	1.3	22
17	Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform. Advanced Biology, 2020, 4, 1900162.	3.0	19
18	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precision Oncology, 2020, 4, 20-31.	3.0	19

#	ARTICLE	IF	CITATION
19	Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!. Cells, 2020, 9, 2486.	4.1	16
20	Nanobody-Based Quantification of GTP-Bound RHO Conformation Reveals RHOA and RHOC Activation Independent from Their Total Expression in Breast Cancer. Analytical Chemistry, 2021, 93, 6104-6111.	6.5	4
21	Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. Clinical Chemistry, 2022, 68, 973-983.	3.2	2
22	A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective Towards the Cellular RHOB GTP-Bound Conformation. SSRN Electronic Journal, 0 , , .	0.4	1
23	Abstract 3985: Dynamic changes of tumor-derived extracellular vesicles and related RNAs in blood samples of NSCLC patients. , 2019, , .		O